Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchNot Yet RecruitingNCT07392528
What this trial is testing

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Who this might be right for
Neuromyelitis Optica Spectrum DisordersMultiple SclerosisMyasthenia Gravis
Tianjin Huanhu Hospital 15
Testing effectiveness (Phase 2)Looking for participantsNCT07009002
What this trial is testing

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Who this might be right for
B Cell Lymphoma
Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06481735
What this trial is testing

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Who this might be right for
Acute Lymphocytic Leukemia
Chinese PLA General Hospital 30
Early research (Phase 1)UnknownNCT03574168
What this trial is testing

CD19-CAR-T Cells in Patients With R/R B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Bioceltech Therapeutics, Ltd. 40
Testing effectiveness (Phase 2)Ended earlyNCT03125577
What this trial is testing

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

Who this might be right for
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute 100
Large-scale testing (Phase 3)UnknownNCT04257175
What this trial is testing

CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Who this might be right for
Acute Myeloid Leukemia
Sheba Medical Center 10
Not applicableTemporarily pausedNCT06310811
What this trial is testing

Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Who this might be right for
SafetyEffective
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 12
Early research (Phase 1)Active Not RecruitingNCT02935257
What this trial is testing

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19

Who this might be right for
Leukemia, Lymphoblastic, Acute, Lymphoma
University College, London 72
Testing effectiveness (Phase 2)Looking for participantsNCT06880913
What this trial is testing

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Who this might be right for
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Early research (Phase 1)Looking for participantsNCT05391490
What this trial is testing

Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

Who this might be right for
Blood Cancer
University College, London 12
Testing effectiveness (Phase 2)Looking for participantsNCT07148791
What this trial is testing

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Who this might be right for
IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders
Chinese PLA General Hospital 9
Early research (Phase 1)WithdrawnNCT06842589
What this trial is testing

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

Who this might be right for
Multi-Drug Resistant Nephrotic SyndromeCAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Testing effectiveness (Phase 2)UnknownNCT04626908
What this trial is testing

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed and RefractoryLymphoid Hematological Malignancies
He Huang 18
Very early researchUnknownNCT05030779
What this trial is testing

CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus ErythematosusAutoimmune Diseases
Zhejiang University 9
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Very early researchNot Yet RecruitingNCT07309744
What this trial is testing

Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease

Who this might be right for
Moderate-to-severe Ulcerative ColitisCrohn's Disease (CD)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Testing effectiveness (Phase 2)Study completedNCT03373071
What this trial is testing

Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL

Who this might be right for
CD19-ALLCD19-LNH
Bambino Gesù Hospital and Research Institute 29
Large-scale testing (Phase 3)Looking for participantsNCT06328777
What this trial is testing

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Who this might be right for
Systemic SclerosisSclerodermaInterstitial Lung Diseases
Cabaletta Bio 37
Early research (Phase 1)Ended earlyNCT03103971
What this trial is testing

HuJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+14 more
Fred Hutchinson Cancer Center 55
Next Page